| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5641805 | ALCON LABS INC | Topical ophthalmic formulations for treating allergic eye diseases |
Jun, 2015
(8 years ago) | |
|
US5641805 (Pediatric) | ALCON LABS INC | Topical ophthalmic formulations for treating allergic eye diseases |
Dec, 2015
(8 years ago) | |
| US7402609 | ALCON LABS INC | Olopatadine formulations for topical administration |
Jun, 2022
(1 year, 10 months ago) | |
|
US7402609 (Pediatric) | ALCON LABS INC | Olopatadine formulations for topical administration |
Dec, 2022
(1 year, 4 months ago) | |
| US6995186 | ALCON LABS INC | Olopatadine formulations for topical administration |
Nov, 2023
(5 months ago) | |
|
US6995186 (Pediatric) | ALCON LABS INC | Olopatadine formulations for topical administration |
May, 2024
(22 days from now) | |
| US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
Pataday Once Daily Relief is owned by Alcon Labs Inc.
Pataday Once Daily Relief contains Olopatadine Hydrochloride.
Pataday Once Daily Relief has a total of 8 drug patents out of which 5 drug patents have expired.
Expired drug patents of Pataday Once Daily Relief are:
- US5641805
- US5641805*PED
- US7402609
- US7402609*PED
- US6995186
Pataday Once Daily Relief was authorised for market use on 22 December, 2004.
Pataday Once Daily Relief is available in solution/drops;ophthalmic dosage forms.
Pataday Once Daily Relief can be used as treatment of ocular itching associated with allergic conjunctivitis, method of treating allergic conjunctivitis.
The generics of Pataday Once Daily Relief are possible to be released after 19 May, 2032.
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 December, 2004
Treatment: Method of treating allergic conjunctivitis; Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
PATADAY ONCE DAILY RELIEF family patents
